Povarnina et al., 2023 - Google Patents
Сhronically Administered BDNF Dipeptide Mimetic GSB-106 prevents the depressive-like behavior and memory impairments after transient middle cerebral artery …Povarnina et al., 2023
View PDF- Document ID
- 5162787175889618170
- Author
- Povarnina P
- Antipova T
- Logvinov I
- Gudasheva T
- Seredenin S
- Publication year
- Publication venue
- Current Pharmaceutical Design
External Links
Snippet
Background: A dipeptide mimetic of the BDNF loop 4, bis (N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, GSB-106, was designed and synthesized by VV Zakusov Research Institute of Pharmacology. The compound activated in vitro TrkB, MAPK/ERK, PI3K/AKT, and …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lourenco et al. | Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models | |
| Bi et al. | Expanding the role of proteasome homeostasis in Parkinson’s disease: beyond protein breakdown | |
| Povarnina et al. | Сhronically Administered BDNF Dipeptide Mimetic GSB-106 prevents the depressive-like behavior and memory impairments after transient middle cerebral artery occlusion in rats | |
| Miller | Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface | |
| Morioka et al. | Amitriptyline up‐regulates connexin43‐gap junction in rat cultured cortical astrocytes via activation of the p 38 and c‐Fos/AP‐1 signalling pathway | |
| Liu et al. | Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis | |
| Miyazaki et al. | Astrocyte‐derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity | |
| Kimbler et al. | Activation of P2X7 promotes cerebral edema and neurological injury after traumatic brain injury in mice | |
| Binukumar et al. | Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson’s disease | |
| Liu et al. | α7 Nicotinic acetylcholine receptor-mediated anti-inflammatory effect in a chronic migraine rat model via the attenuation of glial cell activation | |
| Ziegler et al. | Brainstem origins of glutamatergic innervation of the rat hypothalamic paraventricular nucleus | |
| Zhang et al. | Combined use of spatial restraint stress and middle cerebral artery occlusion is a novel model of post-stroke depression in mice | |
| Fujikawa et al. | Enteric glial cells are associated with stress‐induced colonic hyper‐contraction in maternally separated rats | |
| García et al. | Ischaemic preconditioning in the rat brain: effect on the activity of several initiation factors, Akt and extracellular signal‐regulated protein kinase phosphorylation, and GRP78 and GADD34 expression | |
| BK et al. | TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity | |
| Lesné et al. | Akt-dependent expression of NAIP-1 protects neurons against amyloid-β toxicity | |
| Kansara et al. | Early diagnosis and therapy of Parkinson’s disease: can disease progression be curbed? | |
| Ma et al. | Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki‐16425, a lysophosphatidic acid 1 receptor antagonist | |
| Song et al. | VIP enhances phagocytosis of fibrillar beta-amyloid by microglia and attenuates amyloid deposition in the brain of APP/PS1 mice | |
| Qiu et al. | Vav1 promotes inflammation and neuronal apoptosis in cerebral ischemia/reperfusion injury by upregulating microglial and NLRP3 inflammasome activation | |
| Zhao et al. | R egion‐specific deletions of the glutamate transporter GLT 1 differentially affect nerve injury‐induced neuropathic pain in mice | |
| Kramer et al. | Reduced GABAA receptor α6 expression in the trigeminal ganglion enhanced myofascial nociceptive response | |
| Kim | Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson's disease | |
| Quansah et al. | Chronic methylphenidate preferentially alters catecholamine protein targets in the parietal cortex and ventral striatum | |
| He et al. | RIP3 Inhibition ameliorates chronic constriction injury-induced neuropathic pain by suppressing JNK signaling |